Skip to content
  • Insights Newsletter

    Always Be a Step Ahead

    Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.

    Subscribe to AMI's Insights Newsletter Today.

     

  • Login
  • Contact
  • Subscribe
  • Insights Newsletter

    Always Be a Step Ahead

    Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.

    Subscribe to AMI's Insights Newsletter Today.

     

  • Login
Access Market IntelligenceAccess Market Intelligence
  • Menu
  • About
    • Dr. Randy Vogenberg
    • John Santilli
    • News Announcements
    • Contact
  • Shop Reports
    • Filter By
      • Discounted
      • Latest Releases
    • Report Topic or Type
      • Ebooks
      • Provider Trends
      • Payor Trends
      • Purchaser Trends
      • Market Access & Distribution
  • Solutions
    • Data and Intelligence Platforms
      • Employer Sales Initiatives
    • Advisory and Consulting Services
      • Virtual Advisory Board for Healthcare
      • Strategy Development
      • Health Benefit Training
      • Custom Market Research
    • Specialty Pharmacy Database
  • Resources
    • Insights Blog
    • Sample Reports
    • Free Publications
  • Specialty Pharmacy Database
    • Blog – Specialty Pharmacy
    • SPD Case Study
    • SPD Request for Information
  • $0.00 0
    • No products in the cart.

  • Shop
  • 0

    Cart

    No products in the cart.

Tag Archives: high-cost

Specialty Drug, Specialty HUBs

CareMetx, LLC’s OutcomeRx Launches a Reinsurance Product for Cell and Gene Therapies

Posted on November 20, 2020 by John Santilli
20
Nov

OutcomeRx focuses on engaging with biotech companies to think through, structure, and manage value-based agreements

Continue reading →
Posted in Specialty Drug, Specialty HUBs  |  Tagged biotech, CareMext, careve-out, cell therapy, Crum & Forster, deductible, gene therapy, high-cost, Hub services, insurance, insurer, Ironshare, LCA, Leber Congenital Amaurosis, Luxturna, OutcomeRx, PAACT, patient, patient access, patient engagement, reinsurance, retinal disorder, Risk, specialty drug, Spinraza, stop loss, Zolgensma

Copyright 2023 © Access Market Intelligence. All Rights Reserved  |  Terms of Service 

  • Login
  • Home
  • Reports
    • View Samples
    • What’s New
    • On Sale
    • eBooks
    • By Market
      • Payor
      • Purchaser
      • Provider
      • Market Access & Distribution
  • Services
    • Virtual Advisory Board
    • Strategy Development
    • Health Benefit Training
    • Market Research
  • Data Solutions
    • Specialty Pharmacy Database (SPD)
    • Employer Sales Initiatives
  • Resources
    • Blog
    • Free Downloads
  • About
    • Contact

Login

Lost your password?

Register